Financial and clinical implications of xromi as a new commercial liquid formulation of hydroxyurea

Research
Written By Christine Briscoe

Authors: Lydia Musula, Ryan Hitte, Melissa Graves, Manpreet Kochhar, Allison McGirr-Crowley, Michael Duprey, Patrick McGann

Published: November 3, 2025

Click Here to Read More
Christine Briscoe
Previous

Evaluating the efficacy of brief neurocognitive assessments in adults and adolescents with sickle cell disease
Next

Reclaiming the clinical social work role: A call for reform in sickle cell disease psychosocial care